The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
I’m completely out of my depth with the workings of mRNA therapeutics, and I might have got the wrong end of the stick, but I was interested to find following URL’s confirming the use of Affimers in a previous development of Moderna’s influenza mRNa vaccine.
It got me wondering if today’s announcement of an mRNA Covid vaccine from Moderna included Affimers... although after much searching I cannot find any further evidence!
I guess that if Moderna’s vaccine used Affimer tech, then Avacta would have needed to RNS?
But, posted for interest:
Investor research note in 2017:
https://www.hardmanandco.com/research/corporate-research/de-risking-of-the-partnership-with-moderna/
Moderna was the first to enter into an agreement with Avacta to use the Affimer technology, in tandem with Moderna’s mRNA drug delivery platform. Moderna has just disclosed *Phase I trial data for its mRNA technology which is the first public evidence that it works, which meaningfully de-risks the partnership plans to deliver Affimer therapeutics using mRN
*Moderna’s Phase I trial against influenza using an mRNA vaccine.
Proactive investor note in 2019
https://www.proactiveinvestors.co.uk/companies/news/213871/avacta-says-partner-moderna-takes-collaboration-to-next-level-213871.html
“Given Moderna’s mRNA-based approach, we could see human safety data from Moderna before Avacta itself enters the clinic with its own Affirmer in 2020, which would further enhance the value of the Affimer therapeutic platform.”
This is likely common knowledge to other bb users, but it had previously escaped my attention... Just read the Avacta 30June20 presentation for about the tenth time, and noticed that Avacta was talking about detailed confidential discussion with governments, not just the government.
Page 29...
“Detailed discussions with regulatory authorities, governments and healthcare providers are ongoing but strictly confidential”
https://avacta.com/wp-content/uploads/2020/09/Avacta-Group-plc-Interim-Results-September-2020-v2.pdf
Oxygen, why would a vaccine, and possibly lots of vaccines, diminish the need for testing? Unless of course a vaccine stops an individual from being infectious, then I’d understand.
Yes Mickey279, there are many boats, and luckily, Avacta holders have a ticket for all of them!
*Bams
*Affimer licensing? How about Danaher mentioned by 91Divoc this morning?
*Professional LFT
*Home Use LFT
*AVA6000 clinical trials (Al said that AVA was worth $1.5B to Avacta on its own)
*LG Chem
*Daewoong
*Undisclosed partnerships
*Other? Al said, significant commercial interest from global IVD companies, bioprocessing companies and reagent suppliers.
For those who seem a little discouraged by the lack of news we’ve been told to expect during Q4, I just wanted to re-post a recent, enlightening and extremely bullish interview with Al.
On 27th October Al said this...
“The Affimer platform is WELL PLACED to respond to the desperate need for COVID-19 testing that currently exists in the world”
https://www.sharebuyers.co.uk/shares/avacta-shares-going-for-growth-world-moving-rapidly-again/
I’m a latecomer to this remarkable company, building up a fairly substantial holding mainly around the current price, and I’m very pleased to have done so. Even though the underlying reasons are extremely unfortunate for the UK and RoW, I regard holding shares in Avacta as one of those rare opportunities that only come along once or twice in a lifetime. And I don’t want to miss it.
Of course, it would be very nice to get the first of the LFT related RNS’s, but they’re not yet overdue (Q4) and even though news is sparse, in my view, it’s still all quite telling. Little snippets here and there tell me that there’s a great deal of infrastructure being put into place in the background, and with government backing, to support the plans Al has so confidently shared with us...
*Bams
*TT BBi / Abingdon
*TT Overseas
*Affimer licensing? How about Danaher mentioned by 91Divoc this morning?
*Professional LFT
*Home Use LFT
*AVA6000 clinical trials (Al said that AVA was worth $1.5B to Avacta on its own)
*LG Chem
*Daewoong
*Undisclosed partnerships
*Al said, significant commercial interest from global IVD companies, bioprocessing companies and reagent suppliers.
*President Biden
*Other
When the news does hit, post TT and batch test, I believe that there’ll be a rapid and well organised supply of millions upon millions of Affimer enhanced LFT tests.
Indeed, the quality of posts on this board is refreshing and very much appreciated. I got another couple of 50k’s yesterday and I’m a very confident holder for the long term. Even if the sp remained artificially low for a while longer, the yield on potential future divi’s at this price should make future investors sit up. I’m impressed with AK and how he and bod are steering this business... in my view, they’re in the right place at the right time, and doing the right things.
Yes, this spread has been in place since about 11:30.
Some fairly large orders being purchased today, including a single buy for £0.5m! But also a high number of smaller orders being sold, presumably by those who can’t stand the wait. The mm’s are happily scooping them up in an otherwise quiet session.
Please forgive the fact that this Alistair Smith interview has been widely shared on the board; but for newer investors I just think it’s awesome to reiterate what Al has said publicly about Avacta within the past week!
A few statements made by Al a week ago ...
“The Affimer platform is WELL PLACED to respond to the desperate need for COVID-19 testing that currently exists in the world.”
“Avacta is working with world-class lateral flow test developers and manufacturers to harness the Affimer reagents that work so well in the ELISA test to create a rapid saliva-based coronavirus test as soon as possible”
https://www.sharebuyers.co.uk/shares/avacta-shares-going-for-growth-world-moving-rapidly-again/
Avacta was looking strong enough before COVID...
Al says, “Avacta is in a position to help shape the future of medicine through powerful new anti-cancer treatments and diagnostics. With appropriate scale-up capital, Avacta will become a multi-billion-dollar life sciences company competing globally with the likes of Roche-Genentech, Thermo-Fisher and Abbott.”
“Avacta’s proprietary technology platforms are addressing unmet needs in healthcare markets worth over $150bn.”
cj... There does seem to be provision in the rules for disclosure information (RNS) to be withheld; primarily where information about impending developments is being communicated in confidence with third parties, including the Gov.
https://www.fca.org.uk/publication/archive/ukla-guidance-manual-april-2002.pdf
Appendix 2 / Annex 1 / para’s 9.4, 9.5, 9.8
I’ve never heard of an RNS being suppressed though!
Thanks Richob, I completely agree with your sentiment.
I’m a relatively new AVCT holder, building up a holding mainly around the current price, and I’m very pleased to have done so. Even though the underlying reasons are extremely unfortunate for the UK and RoW, I regard holding shares in Avacta as one of those rare opportunities that only come along once or twice in a lifetime. And I don’t want to miss it.
Of course, it would be very nice to get the first of the LFT related RNS’s, but they’re not overdue, and even though news is sparse, in my view, it’s still all quite telling. Little snippets here and there tell me that there’s a great deal of infrastructure being put into place in the background, and with government backing, to support the plans Al has so confidently shared with us.
When the news does hit, post TT and batch test, I believe that there’ll be a rapid and well organised supply of millions upon millions of Affimer enhanced LFT tests.